Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Policy and Pricing

Thumbnail
February 18, 2021

Lutonix not above board below the knee, says adcom

Thumbnail
November 18, 2020

Healthineers launches antibody test to track immunity

Article image
Vantage logo
November 11, 2020

Icer adds to Gilead's Veklury woes

Article image
Vantage logo
October 19, 2020

US cuts fees for Covid-19 tests

Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?

Article image
Vantage logo
October 15, 2020

Post-Brexit device rules risk the UK falling behind

The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.

Article image
Vantage logo
September 23, 2020

FDA tightens up digital health oversight

Software-enabled medical devices pose unique challenges to regulators, and the US agency is getting serious about meeting them.

Article image
Vantage logo
August 12, 2020

Moderna shows the value of bulk-buying

The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.

Article image
Vantage logo
August 05, 2020

Moderna prices its Covid-19 vaccine in the luxury range

Article image
Vantage logo
July 30, 2020

Astra shakes things up with Covid-19 pricing disclosure

By signalling that its Covid-19 vaccine could cost just a few dollars Astra could seriously embarrass its competition.

Article image
Vantage logo
July 27, 2020

Market says meh to presidential drug pricing orders

There was a time when President Trump could mention drug pricing controls and move markets. Now, not so much.

Article image
Vantage logo
July 23, 2020

Cut-price drug venture takes aim at Pfizer and Astrazeneca

EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.